A phase 0 trial of this STAT3 decoy (ClinicalTrials.gov #NCT00696176, Table 1) determined that intra-tumoral administration in HNSCC patients inhibited STAT3 driven gene expression. The gene discussed is STAT3; the disease is head and neck squamous cell carcinoma.